Alexandria Real Estate Equities
ARE
$115.69
Share price
-0.70%
Change (1 day)
-6.85%
Change (1 year)
Categories
Alexandria Real Estate Equities, Inc. is a real estate investment trust that invests in office buildings and laboratories.
P/S ratio for Alexandria Real Estate Equities (ARE)
P/S ratio as of April 2024 (TTM): 7.03
According to Alexandria Real Estate Equities 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.03242. At the end of 2023 the company had a P/S ratio of 7.60.
P/S ratio history for Alexandria Real Estate Equities from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 7.60 | -17.6% |
| 2022 | 9.22 | -44.6% |
| 2021 | 16.6 | 30.42% |
| 2020 | 12.8 | 0.15% |
| 2019 | 12.7 | 32.27% |
| 2018 | 9.64 | -13.65% |
| 2017 | 11.2 | 13.55% |
| 2016 | 9.83 | 22.88% |
| 2015 | 8.00 | -9.14% |
| 2014 | 8.80 | 20.55% |
| 2013 | 7.30 | 0.05% |
| 2012 | 7.30 | -14.75% |
| 2011 | 8.56 | -2.37% |
| 2010 | 8.77 | 21.13% |
| 2009 | 7.24 | 39.2% |
| 2008 | 5.20 | -48.94% |
| 2007 | 10.2 | -14.54% |
| 2006 | 11.9 | 26.22% |
| 2005 | 9.44 | 0.05% |
| 2004 | 9.44 | 12.4% |
| 2003 | 8.40 | 21.7% |
| 2002 | 6.90 | 1.27% |
| 2001 | 6.81 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.46 | -65.05% | 🇺🇸 USA |
 Eli Lilly LLY | 20.8 | 195.54% | 🇺🇸 USA |
 Amgen AMGN | 5.00 | -28.97% | 🇺🇸 USA |
 Gilead Sciences GILD | 3.04 | -56.73% | 🇺🇸 USA |
 Illumina ILMN | 4.13 | -41.33% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.18 | -69.07% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | 10.0 | 42.76% | 🇺🇸 USA |